John Cox Sells 5,658 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Posted by Geri Gentry on Sep 10th, 2026

Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) CEO John Cox sold 5,658 shares of the business’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $18.88, for a total transaction of $106,823.04. Following the completion of the sale, the chief executive officer directly owned 357,507 shares of the company’s stock, valued at approximately $6,749,732.16. The trade was a 1.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Dyne Therapeutics Price Performance

NASDAQ:DYN opened at $19.19 on Thursday. Dyne Therapeutics, Inc. has a 52 week low of $11.92 and a 52 week high of $27.31. The company has a debt-to-equity ratio of 0.28, a quick ratio of 12.02 and a current ratio of 12.02. The firm’s 50-day simple moving average is $24.77 and its 200 day simple moving average is $20.52. The firm has a market cap of $3.58 billion, a price-to-earnings ratio of -5.76 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). As a group, sell-side analysts predict that Dyne Therapeutics, Inc. will post -3.47 earnings per share for the current year.

More Dyne Therapeutics News

Here are the key news stories impacting Dyne Therapeutics this week:

Positive Sentiment: Royal Bank of Canada maintained an “outperform” rating, although it reduced its price target from $35 to $30. RBC said Dyne’s DYNE-101, or z-basivarsen, has important differences from Novartis’ program that could support better outcomes. RBC analysis of Dyne’s DM1 approach
Positive Sentiment: Dyne is scheduled to present six- and 12-month ACHIEVE trial data for z-basivarsen at the World Muscle Society and AANEM meetings beginning September 29-30. The company expects topline results from its fully enrolled registrational expansion cohort in the first quarter of 2027. Dyne ACHIEVE data announcement
Neutral Sentiment: JPMorgan downgraded DYN from “neutral” to “underweight” and cut its price target from $17 to $10, while RBC remained bullish. The sharply conflicting views highlight significant uncertainty ahead of Dyne’s clinical updates. JPMorgan downgrade report
Neutral Sentiment: Call-option activity increased dramatically, with traders purchasing more than 20,000 calls versus an average of roughly 464. This may indicate speculative expectations for a rebound or favorable clinical data, but it does not establish a fundamental improvement.
Negative Sentiment: Investors appear to be treating the Novartis Phase 3 failure as a warning for the DM1 drug class, causing a sharp decline in Dyne shares despite the company’s upcoming data. Report on rival DM1 trial failure
Negative Sentiment: Several insiders, including CEO John Cox, reported stock sales. The filings state that the sales were made to cover tax withholding on vested equity awards, reducing their negative significance, but the cluster may add to cautious sentiment.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. T. Rowe Price Investment Management Inc. lifted its stake in Dyne Therapeutics by 523.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock worth $343,085,000 after purchasing an additional 14,727,667 shares during the last quarter. BlackRock Inc. acquired a new stake in shares of Dyne Therapeutics in the 2nd quarter valued at $275,500,000. Jupiter Topco LLC bought a new position in shares of Dyne Therapeutics in the 2nd quarter valued at $266,634,000. Orbis Allan Gray Ltd bought a new position in shares of Dyne Therapeutics in the 4th quarter valued at $93,926,000. Finally, Adage Capital Partners GP L.L.C. acquired a new position in shares of Dyne Therapeutics during the 2nd quarter worth $30,378,000. 96.68% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on DYN shares. Weiss Ratings restated a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Friday, July 17th. Robert W. Baird cut their target price on Dyne Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a research report on Wednesday. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Dyne Therapeutics in a report on Monday, August 17th. TD Cowen started coverage on Dyne Therapeutics in a research report on Friday, June 26th. They issued a “buy” rating on the stock. Finally, Cantor Fitzgerald began coverage on Dyne Therapeutics in a research note on Thursday, July 23rd. They issued an “overweight” rating for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $32.17.

Get Our Latest Stock Analysis on Dyne Therapeutics

About Dyne Therapeutics

(Get Free Report)

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.